Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine

• Jake S. O’Donnell,
• Jake S. O’Donnell,
• Ariel Isaacs,
• Ariel Isaacs,
• Virginie Jakob,
• Celia Lebas,
• James B. Barnes,
• Patrick C. Reading,
• Patrick C. Reading,
• Paul R. Young,
• Paul R. Young,
• Paul R. Young,
• Daniel Watterson,
• Daniel Watterson,
• Daniel Watterson,
• Patrice M. Dubois,
• Nicolas Collin,
• Keith J. Chappell,
• Keith J. Chappell,
• Keith J. Chappell

Affiliations

Jake S. O’Donnell

The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia

Jake S. O’Donnell

The School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia

Ariel Isaacs

The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia

Ariel Isaacs

The School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia

Virginie Jakob

Vaccine Formulation Institute, Geneva, Switzerland

Celia Lebas

Vaccine Formulation Institute, Geneva, Switzerland

James B. Barnes

The WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia

Patrick C. Reading

The WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia

Patrick C. Reading

Department of Microbiology and Immunology, The University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia

Paul R. Young

The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia

Paul R. Young

The School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia

Paul R. Young

Australian Infectious Disease Research Centre, The University of Queensland, Brisbane, QLD, Australia

Daniel Watterson

The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia

Daniel Watterson

The School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia

Daniel Watterson

Australian Infectious Disease Research Centre, The University of Queensland, Brisbane, QLD, Australia

Patrice M. Dubois

Vaccine Formulation Institute, Geneva, Switzerland

Nicolas Collin

Vaccine Formulation Institute, Geneva, Switzerland

Keith J. Chappell

The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia

Keith J. Chappell

The School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia

Keith J. Chappell

Australian Infectious Disease Research Centre, The University of Queensland, Brisbane, QLD, Australia